These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1633 related articles for article (PubMed ID: 19720925)

  • 41. In-line (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) in patients with carcinoma of the sinus/nasal area and orbit.
    Wild D; Eyrich GK; Ciernik IF; Stoeckli SJ; Schuknecht B; Goerres GW
    J Craniomaxillofac Surg; 2006 Jan; 34(1):9-16. PubMed ID: 16343913
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
    Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
    Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
    Börjesson PK; Jauw YW; Boellaard R; de Bree R; Comans EF; Roos JC; Castelijns JA; Vosjan MJ; Kummer JA; Leemans CR; Lammertsma AA; van Dongen GA
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2133-40. PubMed ID: 16609026
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
    Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
    Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET).
    Servois V; Mariani P; Malhaire C; Petras S; Piperno-Neumann S; Plancher C; Levy-Gabriel C; Lumbroso-le Rouic L; Desjardins L; Salmon RJ
    Eur J Surg Oncol; 2010 Feb; 36(2):189-94. PubMed ID: 19775851
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Positron-emission tomography (PET) and PET/CT in head and neck cancer - recommendations of an interdisciplinary consensus conference].
    Kohlfürst S; Markitz M; Raunik W; Eckel HE; Kresnik E; Hausegger K; Salzwimmer M; Gaggl A; Chiari F; Lind P
    Laryngorhinootologie; 2009 Feb; 88(2):84-90. PubMed ID: 19219754
    [TBL] [Abstract][Full Text] [Related]  

  • 47. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients.
    Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Ohbayashi C; Sugimura K
    J Magn Reson Imaging; 2007 Oct; 26(4):1071-80. PubMed ID: 17896365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fever of unknown origin: the role of 18F-FDG PET/CT.
    Keidar Z; Gurman-Balbir A; Gaitini D; Israel O
    J Nucl Med; 2008 Dec; 49(12):1980-5. PubMed ID: 18997040
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
    Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
    J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The additional value of integrated PET/CT over PET in initial lymph node staging of esophageal cancer.
    Kato H; Kimura H; Nakajima M; Sakai M; Sano A; Tanaka N; Inose T; Faried A; Saito K; Ieta K; Sohda M; Fukai Y; Miyazaki T; Masuda N; Fukuchi M; Ojima H; Tsukada K; Oriuchi N; Endo K; Kuwano H
    Oncol Rep; 2008 Oct; 20(4):857-62. PubMed ID: 18813827
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
    Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PET/MDCT.
    Dirisamer A; Schima W; Heinisch M; Weber M; Lehner HP; Haller J; Langsteger W
    Eur J Radiol; 2009 Mar; 69(3):536-41. PubMed ID: 18248928
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Additional value of FDG-PET to contrast enhanced-computed tomography (CT) for the diagnosis of mediastinal lymph node metastasis in non-small cell lung cancer: a Japanese multicenter clinical study.
    Kubota K; Murakami K; Inoue T; Itoh H; Saga T; Shiomi S; Hatazawa J
    Ann Nucl Med; 2011 Dec; 25(10):777-86. PubMed ID: 21901365
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of cervical lymph node recurrence of melanoma of the head and neck.
    Fakhry N; Tessonnier L; Cohen F; Gras R; Grob JJ; Giovanni A; Mundler O; Zanaret M
    Rev Laryngol Otol Rhinol (Bord); 2009; 130(4-5):211-4. PubMed ID: 20597399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer.
    Strobel K; Heinrich S; Bhure U; Soyka J; Veit-Haibach P; Pestalozzi BC; Clavien PA; Hany TF
    J Nucl Med; 2008 Sep; 49(9):1408-13. PubMed ID: 18703604
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
    Goerres GW; Stupp R; Barghouth G; Hany TF; Pestalozzi B; Dizendorf E; Schnyder P; Luthi F; von Schulthess GK; Leyvraz S
    Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):153-62. PubMed ID: 15690223
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
    Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
    J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
    [TBL] [Abstract][Full Text] [Related]  

  • 58. (18)F-FDG-PET/CT of orofacial tumors, a value of whole-body imaging approach.
    Ferda J; Ferdová E; Záhlava J; Walter J; Mukensnabl P; Daum O; Kreuzberg B
    Eur J Radiol; 2010 Feb; 73(2):241-8. PubMed ID: 19101104
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U; Even-Sapir E
    Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT.
    Li J; Kuehl H; Grabellus F; Müller SP; Radunz S; Antoch G; Nadalin S; Broelsch CE; Gerken G; Paul A; Kaiser GM
    J Surg Oncol; 2008 Nov; 98(6):438-43. PubMed ID: 18767120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 82.